Therapeutics Daily
Sunday, December 9th, 2007WireShares of Amgen Inc. fell the most in seven months Friday after the biotech company said it might revise the safety information on its biggest product, anemia drug Aranesp.Amgen fell $3.05, or 5.5%, to $52.10, the most since May 10, when a Food and Drug Administration panel suggested new restrictions ...